ORC2

Across TCGA pan-cancer cohorts, ORC2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ORC2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ORC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ORC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and LUSC are the cancer types where ORC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.148	0.771	<.001	25	view →
UCEC	DFS	Median	II,III,IV	0.922	0.438	.028	8	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ORC2–KIRP (OS)

Open the KIRP breakdown →